Orda?s is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods. For each client, we create billions of proteins and evaluate their properties in silico to reliably and repeatedly deliver the de novo mini-proteins that drug hunters only dream of. We then prove our consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. We help birth novel therapies to reduce patient suffering and improve health. We deliver safer and more effective life-saving treaments. Our flagship solution, miniPRO™ proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods. Orda?s miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to scale-up and manufacture. These proteins are 20x smaller than traditional monoclonal antibodies enabling them to more easily penetrate and effectively treat disease microenvironments. miniPRO™ proteins make up a group of 40~160 amino acid long proteins that independently fold into single domains. The proteins act as self-contained, configurable building blocks and are engineered for the therapeutic modality of choice. We are a human-enabled, machine-driven drug design company that creates bespoke mini-proteins to help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Our deep learning approach goes beyond rational combinatorial methods. We leverage a generative perception engine powered by reinforcement learning and proprietary data sets to translate human-targeted product criter